Orthocell has signed Memorandum of Understanding to increase its equity stake in Marine Biomedical – from 1.7% to 12.0% for a total consideration of AU$1.0 million – securing exclusive first right of refusal over global distribution rights their groundbreaking bone substitute product, PearlBone™.
$30.0 Million Placement to Accelerate Global Commercialisation and Advance Product Portfolio
Orthocell has today announced that it has received firm commitments for a $30 million capital raising via an institutional placement.
Quarterly Report – period ended 30 September 2025
Orthocell has today released its Quarterly Report for the period ended 30 September 2025, outlining a period of continued growth and strong commercial progress.
Orthocell Announces Record Revenue of $3m for September Quarter
Orthocell has announced record quarterly revenue of $3.0 million for the September quarter – our sixth consecutive quarter of record revenue growth.
Orthocell Appoints First Distributor for Remplir™ in US$75m Canadian Market
Orthocell has appointed its first Canadian distributor for Remplir™, signalling the commencement of the Company’s commercial roll out in the US$75m Canadian nerve repair market.
STOCKHEAD | Orthocell flags rapid ‘hockey stick’ revenue growth in the US$1.6 billion US nerve repair market
Orthocell was featured in a Stockhead article by leading biotech journalist Tim Boreham titled “Orthocell flags rapid ‘hockey stick’ revenue growth in the US$1.6 billion US nerve repair market.”
The article explores our global expansion, including the rapid rollout of Remplir in the US following FDA clearance, new international markets such as Canada and Asia, and emerging opportunities in prostate surgery. It also highlights the Company’s strong financial position as we scale globally.
Here’s an excerpt:
“Van Der Wielen notes Orthocell’s revenue has grown at an average annual compound rate of 34% over the past three years. The company is “not too far from heading to profit” as US revenues flow in.
“We are at an inflexion point,” Van Der Wielen says. “We expect to see revenue rates sustainably increase. We are very much focused on the US and couldn’t be happier with the progress and the quality of people we already have employed.”
Global opportunity emerges as Remplir™ is used in nerve-sparing prostate cancer surgery
Orthocell has identified a promising new application for its flagship Remplir™ nerve repair device – for use in nerve-sparing Robotic-Assisted Radical Prostatectomies (RARP).
Remplir™ Real World Evidence study delivers compelling 81% success rate
Orthocell has today released interim results from a new Remplir™ Real World Evidence study, demonstrating an overall treatment success rate of 81.1% following nerve repair procedures.
Commercialisation of Remplir™ into US Market Continues to Build Momentum
Orthocell has today provided update on the continuing successful commercialisation of its flagship nerve repair product Remplir™ in the US.
Orthocell Announces Changes to its Board of Directors
Orthocell has today announced some important changes to its Board of Directors.